BMY May 2025 43.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

5.30

0.00

(0.00%)

As of 10:27AM EDT. Market open.

Loading interactive chart…

Business Wire
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J., June 18, 2024--Bristol Myers Squibb Announces Dividend
Zacks
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Business Wire
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
PRINCETON, N.J., June 13, 2024--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive....